Press Enter to Main Content
您的瀏覽器似乎不支援JavaScript語法,但沒關係,這裡的JavaScript語法並不會影響到內容的陳述, 如需要選擇字級大小,IE6請利用鍵盤按住ALT鍵+ V → X → (G)最大(L)較大(M)中(S)較小(A)小,來選擇適合您的文字大小, 而IE7或Firefox瀏覽器則可利用鍵盤 Ctrl + (+)放大(-)縮小來改變字型大小,如需要回到上一頁可使用瀏覽器提供的 Alt+左方向鍵(←) 快速鍵功能,列印可使用瀏覽器提供的(Ctrl+P)功能。
  • facebook
  • line
  • twitter
  • Print
  • Back

A Pilot Plan of E Platform for Review & Submission (E-PRESS)

  • Data Source:Food and Drug Administration, Ministry of Health and Welfare
  • Created:2017-11-16
  • Last Updated:2017-11-16

Taiwan Food and Drug Administration (TFDA) announced a pilot plan of E Platform for Review and Submission (called E-PRESS) on October 23, 2017, which as we all know the e-submission.

In general, the e-submission is not only to focus on the minimization of paper use during the exchange of information between applicants and authorities, but also to enhance the quality and efficiency of the medicinal product registration process, shorten innovated product review time.

TFDA has established an electronic platform for review and submission. In this pilot plan, it is also to provide priority review as an incentive for license holders to increase the E-PRESS utilization. Furthermore, TFDA will continue to evaluate the effectiveness of E-PRESS and revise it if necessary.  

The portal page of E-PRESS, operating manual and relevant Q&A can be found on the following link :( http://e-sub.fda.gov.tw/dohclient/Manager/Login.aspx)